Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises IRLAB Therapeutics in connection with share issues
Mandate

Vinge advises IRLAB Therapeutics in connection with share issues

December 13, 2019 Capital Markets and Public M&A

Vinge advises IRLAB Therapeutics in connection with a directed share issue of SEK 70 million and a rights issue of approximately SEK 145 million.

The directed share issue was subscribed for by a number of institutional and qualified investors on the basis of an accelerated book building process. The rights issue is expected to be completed during the first quarter of 2020.

IRLAB Therapeutics is a research and development company, listed on Nasdaq First North Premier Growth Market, focused on development of novel therapies for the treatment of neurodegenerative diseases, in particular Parkinson’s disease and dementia.

Vinge’s team has consisted of Dain Hård Nevonen, Nils Fredrik Dehlin, Stephanie Stiernstedt, Stojan Arnerstål, Anna Thoms and Maria Schultzberg.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

 Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

 Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025